Get the Stockscreener App
16.14
3.99%
-0.67
Pre-market:
16.14
Anbio Biotechnology stock is traded at $16.14, with a volume of 41,495.
It is down -3.99% in the last 24 hours and down -40.09% over the past month.
Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).
See More
Previous Close:
$16.81
Open:
$16.43
24h Volume:
41,495
Relative Volume:
1.50
Market Cap:
$708.40M
Revenue:
$9.74M
Net Income/Loss:
$7.19M
P/E Ratio:
98.59
EPS:
0.1637
Net Cash Flow:
$2.25M
1W Performance:
-0.12%
1M Performance:
-40.09%
6M Performance:
-42.38%
1Y Performance:
+79.13%
1-Day Range:
$15.35
$17.70
1-Week Range:
$14.66
$17.70
52-Week Range:
$8.94
$55.65
Anbio Biotechnology Stock (NNNN) Company Profile
Name
Anbio Biotechnology
Sector
Industry
Phone
-
Address
-
Compare NNNN vs ISRG, BDX, ALC, MDLN, RMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NNNN
Anbio Biotechnology
|
16.14 | 737.81M | 9.74M | 7.19M | 2.25M | 0.1637 |
ISRG
Intuitive Surgical Inc
|
417.07 | 147.53B | 10.58B | 3.00B | 2.83B | 8.2437 |
BDX
Becton Dickinson Co
|
145.16 | 40.10B | 21.37B | 1.41B | 3.07B | 3.9437 |
ALC
Alcon Inc
|
65.84 | 32.33B | 10.63B | 819.00M | 1.59B | 1.6577 |
MDLN
Medline Inc
|
37.09 | 31.57B | 29.14B | 1.07B | 1.05B | 1.1956 |
RMD
Resmed Inc
|
193.94 | 27.96B | 5.54B | 1.52B | 1.74B | 10.37 |
Anbio Biotechnology Stock (NNNN) Latest News
Anbio Biotechnology Soars as Geopolitics Ignite Rebound - TipRanks
Why Anbio Biotechnology Class A Shares Are Sliding - TipRanks
Anbio Biotechnology (NNNN) director ZHANG MICHAEL W.C files initial Form 3 - Stock Titan
Director David H. Hsu files initial Form 3 at Anbio Biotechnology (NNNN) - Stock Titan
Why Anbio Biotechnology Shares Keep Sinking Today - TipRanks
Why Anbio Biotechnology Class A Shares Are Sinking - TipRanks
Anbio’s Stock Has Been On A Wild Run Since Its IPO - Finimize
Anbio Biotechnology (NNNN) Faces Sharp Pullback: Key Levels and Market Sentiment After 14.88% DeclinePercent Above MA - newsline.com
Anbio Biotechnology (NNNN) Drops 7.2% as Selling Pressure IntensifiesOpening Range Breakout - newsline.com
Why Anbio Biotechnology Class A Stock Is Sliding - TipRanks
Why Anbio Biotechnology NNNN Shares Are Surging Now - TipRanks
Why Anbio Biotechnology Shares Are Tumbling Today - TipRanks
Anbio Biotechnology Holds Steady Near $34.41 as Trading Volume Remains ModerateThrowback Trade - The Legal Advocate
Why Anbio Biotechnology Class A Shares Are Surging - TipRanks
Anbio Biotechnology (NNNN) Stock Forecast and Price Target 2026 - MarketBeat
Anbio Biotechnology (NNNN) Holds Near Support as Selling Pressure ModeratesAAII Bearish - newsline.com
Assessing Anbio Biotechnology (NNNN) Valuation After Strong Recent Share Price Momentum - simplywall.st
Anbio Biotechnology (NNNN) Share Price Forecast & Price Target - Investing.com UK
Why Anbio Biotechnology Shares Are Tumbling Now - TipRanks
Anbio Biotechnology Shareholders Approve Sweeping Capital and Governance Changes - TipRanks
Control shifts as Anbio (NNNN) boosts Class B voting power - Stock Titan
Why Anbio Biotechnology Shares Won’t Stop Climbing - TipRanks
Uncovering 3 Undiscovered Gems in the US Market - Yahoo Finance
Top Hemab Therapeutics (COAG) Competitors 2026 - MarketBeat
TradingKey - TradingKey
Number of shareholders of Anbio Biotechnology – NASDAQ:NNNN - TradingView
Why Anbio Biotechnology Class A Shares Keep Sliding - TipRanks
Why are smart money investors paying attention to Anbio (NNNN)? (Momentum Fading) 2026-05-07Overvalued Stocks - Newser
Hemab Therapeutics Hldgs (COAG) Stock Analysis Report | Financials & Insights - Benzinga
Why Anbio Biotechnology Class A Shares Are Jumping - TipRanks
Free cash flow per share of Anbio Biotechnology Class A – FWB:N3B - TradingView
Top LosersStock ScreenerSnapshot - Finviz
Anbio Biotechnology Calls May 15 Shareholder Votes on Sweeping Capital and Governance Overhaul - The Globe and Mail
Anbio Biotechnology (NNNN) seeks huge capital increase and 500-vote Class B shares - Stock Titan
Top Maplight Therapeutics (MPLT) Competitors 2026 - MarketBeat
Why Anbio Biotechnology Shares Are Suddenly Surging - TipRanks
Anbio (NNNN) Stock Volume Drop (Buying Pressure) 2026-04-22Swing Entry Signals - newsline.com
Anbio Biotechnology posts solid FY25 results, diversifies portfolio - MSN
Cany Xu Net Worth (2026) - GuruFocus
Nancy Hartzler Net Worth (2026) - GuruFocus
Suki Song Net Worth (2026) - GuruFocus
Michael Lau Net Worth (2026) - GuruFocus
Chris Tian Net Worth (2026) - GuruFocus
Why Anbio Biotechnology Shares Are Sliding Fast - TipRanks
Anbio Biotechnology (NASDAQ:NNNN) Trading Down 5.5%Here's What Happened - MarketBeat
Assessing Anbio Biotechnology (NNNN) Valuation After Sharp Swings And A Rich Price To Book Multiple - simplywall.st
Anbio Biotechnology Broadens Test Portfolio And Shifts Risk Profile - Sahm
Is Anbio (NNNN) Stock Discounted Now | Price at $27.63, Up 1.96%Day Trade Opportunities - newsline.com
Anbio Biotechnology Posts Solid FY25 Results, Diversifies Portfolio - Sahm
Is Anbio (NNNN) Stock Good for Beginners | Price at $26.77, Down 0.28%Retail Driven Moves - The Legal Advocate
Anbio Biotechnology Stock (NNNN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.68%
0.71%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):